What Prescription Drug Pricing Can Learn From Value-Based Care Models
As pharma becomes part of the value-based revolution, there are several lessons that can be learned from the ongoing development of value-based care.
2023 Likely To Be a Crucial Year for Pharma—and Insurers
2023 is shaping up to be a crucial year for everyone involved – and affected – by the pharmaceutical industry. It's likely to be a year of experimentation for payers – and defensiveness for drug makers.
presented by
The Top 5 Home Care Franchise Opportunities in the U.S.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
Biden’s New Executive Order Could Usher in an Era of Fair and Equitable Drug Pricing
By leveraging its large membership, Medicare could by embracing value-based contracting significantly influence the pharmaceutical market, pitting competing drugs against each other, or encouraging pharmaceutical makers to figure out ways to deliver drugs more cheaply.
Aduhelm’s loss is a win for value-based drug pricing
Value-based pricing could have shown us with more certainty the real level of effectiveness of Aduhelm. Maybe it is worth paying something for; and value-based contracts are the only way to figure that out.